UNSPSC 51302404: Nystatin

This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BDF1O1C72E. European Medicines Agency schedules Nystatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03475MIG. Nystatin generally arises in the molecular formula C47H75NO17.

The term NYSTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) NYSTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nystatin under HS 29419000 and SITC 54139. As of Q4 2014, NYSTATIN remains the US FDA Preferred Term for this commodity. Nystatin bears US NLM identifiers UMLS ID C0028741 and NCI Concept Code C710.

UNSPSC 51302404 Nystatin is a Commodity code for a specific antifungal medication, but the single recent state and local opportunity tagged under it—the City of Tampa Fire Rescue Department's ITB 25-P-00157 for medical aid supplies—does not include nystatin in its scope. The Tampa solicitation covers a broad range of first aid and emergency medical supplies (antiseptic sprays, hydrogen peroxide, aspirin, pain relievers, bandages, first aid kits, emergency blankets) but makes no mention of antifungal or nystatin-based products. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope.

The City of Tampa's April 2026 ITB is the only recent opportunity in the source, with a $100,000 total department budget and response due April 9, 2025. The procurement includes set-aside provisions for City-certified Small Local Business Enterprises (SLBEs) offering a 5% bid discount (capped at $10,000) and Underutilized Woman and Minority Owned Business Enterprises (U-WMBEs) with a 5% discount (capped at $20,000), targeting underutilized businesses owned by African American, Hispanic, Asian, Native American, and women business owners. The contract structure offers an initial one-year award period with potential for two additional one-year renewals, and all medications must carry a minimum nine-month expiration date from acceptance. Bidders must submit documentation including business licenses, minority business status certification, and conflict of interest disclosures, and any work with WMBE or SLBE subcontractors requires subcontract agreements or purchase orders before commencement.